Lonza, a global manufacturing partner to the pharma, biotech industries, has invested in additional microbial development capabilities in Switzerland to support increased capacity of development services targeting microbial-derived proteins, with expanded lab space and equipment to be in use by the end of 2021.   The current extension will support new projects in Lonza’s existing manufacturing assets as well as the previously announced mid-scale microbial capacity expansion. As microbial expre...